Litigation & Arbitration
Jun. 7, 2023
Former Gilead GC explains patent suit settlements with competitors
Gilead is accused of forging a deal with Teva, which had challenged many of Gilead's vulnerable patents, to delay Teva's marketing of its generic medicine and afford it time to move its customers away from its current version of drugs to a newer medicine that did not have generic versions.
A former general counsel for Gilead Sciences Inc. testified Tuesday about settlements the company agreed to with generic pharmaceutical manufacturers to resolve patent litigation, the key issue in the ongoing lawsuit alleging Gilead conspired to create a pay-to-delay scheme for its HIV medication.
Senior U.S. District Judge Edward M. Chen instructed the jurors that Gilead asserted attorney-client privilege so they will not hear Gilead employees or communications on the strength or...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In